Literature DB >> 8589469

Fungal infections in left ventricular assist device recipients. Incidence, prophylaxis, and treatment.

D J Goldstein1, N G el-Amir, R C Ashton, K Catanese, R A Rose, H R Levin, M C Oz.   

Abstract

The authors reviewed the charts of 26 recipients of a left ventricular assist device to determine the incidence of fungal infections and the clinical course of these patients. Nine patients (35%) had positive fungal cultures. Of these, six had clinical infections and three were colonized asymptomatically. Three of the six infected patients (including one with mediastinal sepsis and another requiring left ventricular assist device replacement for intractable fungemia) underwent orthotopic heart transplantation after successful therapy. Of the remaining three, one died of a thromboembolic stroke (probably septic in nature), one died secondary to driveline rupture, and the third succumbed to culture-negative sepsis. Two of the colonized patients underwent transplantation, and the third succumbed to perioperative right sided circulatory failure and hypoxia. Positive fungal cultures were a common finding in our series. Because of a significant incidence of fungal infection-related morbidity, the authors revised their pre operative and post operative protocol to include: 1) 2 weeks of fluconazole therapy (200 mg intravenously daily) for patients receiving broad spectrum antibiotics and for those with evidence of preoperative fungal colonization; 2) daily dressing changes around drivelines; 3) daily nystatin swish and swallow; and 4) empiric fluconazole treatment for culture-negative sepsis. Using this protocol, three left ventricular assist device recipients received prophylactic fluconazole and had no evidence of fungal morbidity or mortality on short-term follow-up.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8589469

Source DB:  PubMed          Journal:  ASAIO J        ISSN: 1058-2916            Impact factor:   2.872


  7 in total

Review 1.  Antifungal prophylaxis during neutropenia and immunodeficiency.

Authors:  O Lortholary; B Dupont
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

2.  Risk factors and outcomes of fungal ventricular-assist device infections.

Authors:  Saima Aslam; Maria Hernandez; John Thornby; Barry Zeluff; Rabih O Darouiche
Journal:  Clin Infect Dis       Date:  2010-03-01       Impact factor: 9.079

Review 3.  Endocarditis in left ventricular assist device.

Authors:  Braghadheeswar Thyagarajan; Monisha Priyadarshini Kumar; Rutuja R Sikachi; Abhinav Agrawal
Journal:  Intractable Rare Dis Res       Date:  2016-08

4.  Clinical manifestations and management of left ventricular assist device-associated infections.

Authors:  Juhsien Jodi C Nienaber; Shimon Kusne; Talha Riaz; Randall C Walker; Larry M Baddour; Alan J Wright; Soon J Park; Holenarasipur R Vikram; Michael R Keating; Francisco A Arabia; Brian D Lahr; M Rizwan Sohail
Journal:  Clin Infect Dis       Date:  2013-08-13       Impact factor: 9.079

Review 5.  Perioperative pharmacotherapy in patients with left ventricular assist devices.

Authors:  Nicholas C Dang; Yoshifumi Naka
Journal:  Drugs Aging       Date:  2004       Impact factor: 4.271

6.  Ventricular assist devices as bridge to heart transplantation: impact on post-transplant infections.

Authors:  Delphine Héquet; Georg Kralidis; Thierry Carrel; Alexia Cusini; Christian Garzoni; Roger Hullin; Pascal R Meylan; Paul Mohacsi; Nicolas J Mueller; Frank Ruschitzka; Piergiorgio Tozzi; Christian van Delden; Maja Weisser; Markus J Wilhelm; Manuel Pascual; Oriol Manuel
Journal:  BMC Infect Dis       Date:  2016-07-08       Impact factor: 3.090

Review 7.  In Full Flow: Left Ventricular Assist Device Infections in the Modern Era.

Authors:  Radoslav Zinoviev; Christopher K Lippincott; Sara C Keller; Nisha A Gilotra
Journal:  Open Forum Infect Dis       Date:  2020-04-17       Impact factor: 3.835

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.